First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma.
暂无分享，去创建一个
A. Ravaud | B. Melichar | A. Santoro | C. Szczylik | P. Pisa | B. Escudier | S. Bracarda | A. Płużańska | P. Koralewski | C. Chevreau | B. Melichar | S. Négrier | E. Sevin | J. Mckendrick | R. Delva | R. Delva | M. Filipek | B. Escudier